



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

November 2021





© 2022 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2021 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

November 2021

N = 7464



Health Authority	Male	Female	All
FRASER	1479	440	1919
INTERIOR	452	102	554
NORTHERN	149	78	227
VANCOUVER COASTAL	3308	449	3757
VANCOUVER ISLAND	790	171	961
	6178	1240	7418
		Unknown/not stated:	46
		Total:	7464

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (November 2016 - November 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (November 2016 - November 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (November 2016 - November 2021)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (November 2016 - November 2021)






1.6 Percent Distribution of Active Participants by CD4 Count (November 2016 - November 2021)






1.7 Percent Distribution of Inactive Participants by CD4 Count (November 2016 - November 2021)






1.8 Active and Inactive Participants (November 2016 - November 2021)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (November 2016 - November 2021)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (November 2016 - November 2021)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(November 2016 - November 2021)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (November 2016 - November 2021)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(November 2016 - November 2021)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (November 2016 - November 2021)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(November 2016 - November 2021)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (November 2016 - November 2021)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(November 2016 - November 2021)






1.18 Baseline CD4 for Antiretroviral First Starts
(November 2016 - November 2021)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (November 2016 - November 2021)






1.20 Cumulative Resistance Testing Results by Resistance Category (November 2016 - November 2021)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (November 2016 - November 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	5	0	5	2	570	5	<40	4
1988	31	5	0	5	3	350	5	<40	3
1989	29	51	1	52	26	505	50	<40	3
1990	27	53	1	54	32	520	52	<40	3
1991	27	37	3	40	21	650	37	<40	3
1992	27	58	5	63	30	585	59	<40	3
1993	26	125	14	139	89	560	135	<40	3
1994	25	73	12	85	54	555	81	<40	3
1995	25	122	20	142	95	560	131	<40	3
1996	23	310	45	355	226	600	332	<40	3
1997	21	269	33	302	197	620	279	<40	3
1998	20	187	40	227	148	570	204	<40	3
1999	20	155	38	193	120	515	173	<40	3
2000	20	118	29	147	97	600	136	<40	3
2001	20	115	26	141	90	630	126	<40	3
2002	19	119	25	144	98	610	129	<40	3
2003	18	139	27	166	99	620	158	<40	3
2004	17	147	38	185	131	610	173	<40	3
2005	16	179	40	219	154	660	200	<40	3
2006	15	169	39	208	135	610	187	<40	3
2007	14	230	49	279	203	650	248	<40	3
2008	13	276	64	340	236	645	312	<40	3
2009	12	300	63	363	252	630	335	<40	3
2010	11	259	66	325	236	650	299	<40	3
2011	10	325	74	399	259	700	354	<40	3
2012	9	274	63	337	224	700	299	<40	3
2013	8	249	65	314	222	670	284	<40	3
2014	7	270	48	318	200	680	276	<40	3
2015	6	276	45	321	209	700	284	<40	3
2016	5	266	51	317	212	680	282	<40	3
2017	4	216	32	248	173	630	220	<40	3
2018	3	183	54	237	167	710	215	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	2	232	40	272	203	660	253	<40	3
2020	1	188	53	241	177	680	222	<40	3
2021	1	210	41	251	198	564	235	<40	3
Total:		6190	1244	7434					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1729	610
FEB-2020	7329	776	1882	<40	1417	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	577	600
MAY-2020	7397	776	1186	<40	892	600
JUN-2020	7368	784	1558	<40	1148	620
JUL-2020	7333	794	1918	<40	1437	610
AUG-2020	7254	791	1848	<40	1332	630
SEP-2020	7233	784	1735	<40	1243	620
OCT-2020	7265	776	1782	<40	1309	630
NOV-2020	7340	763	1858	<40	1284	610
DEC-2020	7346	752	1542	<40	1085	630
JAN-2021	7384	746	1942	<40	1391	630
FEB-2021	7377	748	1787	<40	1273	630
MAR-2021	7432	743	2016	<40	1425	620
APR-2021	7417	746	1828	<40	1322	633
MAY-2021	7452	742	1868	<40	1304	630
JUN-2021	7456	738	1880	<40	1346	610
JUL-2021	7461	744	1820	<40	1337	640
AUG-2021	7471	740	1981	<40	1342	630
SEP-2021	7445	749	1762	<40	1224	630
OCT-2021	7446	755	1857	<40	1259	630
NOV-2021	7464	748	2020	<40	1295	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	819	142	75	<40	65	470
SEP-2020	871	137	93	<40	71	610
OCT-2020	866	178	87	<40	75	570
NOV-2020	794	192	78	<40	63	510
DEC-2020	799	186	65	<40	55	420
JAN-2021	782	203	73	<40	56	525
FEB-2021	795	199	69	<40	56	510
MAR-2021	780	251	89	<40	70	630
APR-2021	813	258	73	<40	58	615
MAY-2021	792	276	73	<40	65	530
JUN-2021	791	272	65	57	48	535
JUL-2021	794	278	52	102	37	530
AUG-2021	800	273	53	<40	40	645
SEP-2021	842	231	65	<40	42	605
OCT-2021	839	248	77	<40	58	540
NOV-2021	823	274	79	<40	59	450

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7345	662	9	9	125	149	-30	14042
JUL-2020	7308	729	15	12	160	189	-37	14074
AUG-2020	7222	819	18	11	168	240	-86	14094
SEP-2020	7193	871	19	8	229	241	-29	14115
OCT-2020	7225	866	20	13	222	176	32	14136
NOV-2020	7309	794	12	11	245	155	84	14162
DEC-2020	7323	799	10	13	205	191	14	14191
JAN-2021	7361	782	14	9	205	159	38	14211
FEB-2021	7353	795	15	13	186	190	-8	14235
MAR-2021	7407	780	15	24	203	156	54	14272
APR-2021	7393	813	13	9	165	172	-14	14297
MAY-2021	7422	792	14	14	177	143	29	14326
JUN-2021	7439	791	7	15	186	175	17	14352
JUL-2021	7440	794	9	12	170	168	1	14372
AUG-2021	7439	800	16	12	174	167	-1	14394
SEP-2021	7405	842	14	9	173	197	-34	14424
OCT-2021	7406	839	16	6	187	171	1	14447
NOV-2021	7434	823	11	15	197	173	28	14473

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6735	477	58	7329	0.81%	91.90%	6.51%	0.79%	100.00%
MAR-2020	60	6790	487	50	7387	0.81%	91.92%	6.59%	0.68%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6806	481	50	7397	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6774	484	51	7368	0.80%	91.94%	6.57%	0.69%	100.00%
JUL-2020	61	6753	471	48	7333	0.83%	92.09%	6.42%	0.65%	100.00%
AUG-2020	70	6677	457	51	7255	0.96%	92.03%	6.30%	0.70%	100.00%
SEP-2020	85	6641	456	52	7234	1.18%	91.80%	6.30%	0.72%	100.00%
OCT-2020	107	6645	462	51	7265	1.47%	91.47%	6.36%	0.70%	100.00%
NOV-2020	162	6673	456	49	7340	2.21%	90.91%	6.21%	0.67%	100.00%
DEC-2020	180	6656	461	49	7346	2.45%	90.61%	6.28%	0.67%	100.00%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6652	448	51	7377	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6669	463	51	7432	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6640	465	48	7452	4.01%	89.10%	6.24%	0.64%	100.00%
JUN-2021	326	6613	471	46	7456	4.37%	88.69%	6.32%	0.62%	100.00%
JUL-2021	354	6591	470	46	7461	4.74%	88.34%	6.30%	0.62%	100.00%
AUG-2021	381	6576	472	42	7471	5.10%	88.02%	6.32%	0.56%	100.00%
SEP-2021	398	6537	463	47	7445	5.35%	87.80%	6.22%	0.63%	100.00%
OCT-2021	409	6529	462	46	7446	5.49%	87.68%	6.20%	0.62%	100.00%
NOV-2021	438	6524	459	43	7464	5.87%	87.41%	6.15%	0.58%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine															
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All														
JAN-2020	2	8%	3402	47%	2	8%	3226	45%	0	0%	34	0%	0	0%	1	0%	9	38%	1024	14%	13	54%	2963	41%	22	92%	3763	52%
FEB-2020	3	8%	3351	47%	3	8%	3179	45%	0	0%	33	0%	0	0%	1	0%	16	44%	1169	16%	17	47%	2825	40%	33	92%	3781	53%
MAR-2020	5	14%	3325	46%	5	14%	3160	44%	1	3%	34	0%	0	0%	1	0%	20	56%	1326	18%	11	31%	2719	38%	30	83%	3855	54%
APR-2020	6	24%	3298	46%	5	20%	3137	43%	1	4%	35	0%	0	0%	0	0%	8	32%	1402	19%	11	44%	2637	37%	19	76%	3888	54%
MAY-2020	1	4%	3272	45%	0	0%	3111	43%	0	0%	36	0%	0	0%	0	0%	13	54%	1481	21%	11	46%	2595	36%	23	96%	3914	54%
JUN-2020	5	29%	3242	45%	5	29%	3080	43%	0	0%	33	0%	0	0%	0	0%	4	24%	1585	22%	8	47%	2517	35%	12	71%	3921	55%
JUL-2020	6	19%	3199	45%	4	13%	3039	42%	2	6%	32	0%	0	0%	0	0%	14	44%	1695	24%	12	38%	2420	34%	26	81%	3942	55%
AUG-2020	3	15%	3149	45%	2	10%	2990	42%	0	0%	31	0%	0	0%	0	0%	11	55%	1760	25%	6	30%	2313	33%	17	85%	3914	55%
SEP-2020	3	14%	3121	44%	2	10%	2960	42%	0	0%	31	0%	0	0%	0	0%	13	62%	1869	26%	5	24%	2224	32%	18	86%	3928	56%
OCT-2020	2	10%	3121	44%	2	10%	2944	41%	0	0%	29	0%	0	0%	0	0%	12	57%	1971	28%	7	33%	2135	30%	19	90%	3961	56%
NOV-2020	7	27%	3164	44%	3	12%	2934	41%	1	4%	30	0%	0	0%	0	0%	11	42%	2063	29%	8	31%	2077	29%	19	73%	3990	56%
DEC-2020	3	10%	3151	44%	3	10%	2895	40%	0	0%	29	0%	0	0%	0	0%	14	48%	2143	30%	12	41%	2020	28%	26	90%	4010	56%
JAN-2021	2	10%	3153	44%	1	5%	2880	40%	0	0%	28	0%	0	0%	0	0%	12	60%	2220	31%	6	30%	1962	27%	18	90%	4045	56%
FEB-2021	2	8%	3135	43%	2	8%	2843	39%	0	0%	27	0%	0	0%	0	0%	16	67%	2298	32%	6	25%	1899	26%	22	92%	4061	56%
MAR-2021	8	22%	3140	43%	7	19%	2832	39%	0	0%	24	0%	0	0%	0	0%	23	62%	2368	33%	6	16%	1858	26%	29	78%	4111	57%
APR-2021	2	8%	3137	43%	2	8%	2802	39%	0	0%	25	0%	0	0%	0	0%	17	68%	2422	33%	6	24%	1791	25%	23	92%	4104	57%
MAY-2021	7	24%	3150	43%	3	10%	2784	38%	0	0%	22	0%	0	0%	0	0%	15	52%	2497	34%	10	34%	1759	24%	22	76%	4131	57%
JUN-2021	4	15%	3137	43%	3	12%	2741	38%	0	0%	23	0%	0	0%	0	0%	17	65%	2574	35%	5	19%	1698	23%	22	85%	4153	57%
JUL-2021	3	15%	3126	43%	2	10%	2707	37%	0	0%	23	0%	0	0%	0	0%	13	65%	2627	36%	4	20%	1655	23%	17	85%	4167	57%
AUG-2021	1	5%	3109	43%	1	5%	2667	37%	0	0%	23	0%	0	0%	0	0%	16	73%	2665	36%	5	23%	1632	22%	21	95%	4188	57%
SEP-2021	4	13%	3083	42%	2	7%	2619	36%	1	3%	22	0%	0	0%	0	0%	21	70%	2713	37%	5	17%	1589	22%	26	87%	4186	57%
OCT-2021	5	22%	3089	42%	5	22%	2598	36%	0	0%	20	0%	0	0%	0	0%	13	57%	2759	38%	5	22%	1566	21%	18	78%	4203	58%
NOV-2021	3	12%	3075	42%	2	8%	2556	35%	0	0%	19	0%	0	0%	0	0%	18	72%	2822	39%	4	16%	1538	21%	22	88%	4230	58%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	812 35%	4 67%	1386 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	779 35%	8 100%	1359 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	749 35%	4 80%	1327 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	734 35%	2 67%	1298 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1281 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	694 34%	3 100%	1270 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	677 33%	11 92%	1286 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	548 30%	2 100%	1206 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	538 30%	2 100%	1186 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	519 29%	3 100%	1185 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	511 29%	3 75%	1172 67%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	447 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	438 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	421 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	409 30%	2 67%	293 22%
OCT-2020	0 0%	9 1%	1 100%	461 35%	0 0%	171 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	451 35%	0 0%	171 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	437 34%	0 0%	163 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	143 13%	0 0%	318 28%	2 67%	244 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2642 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2554 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1022 22%	9 69%	2537 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1140 24%	10 42%	2508 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1219 26%	6 35%	2458 52%	1 6%	518 11%	0 0%	29 1%	0 0%	520 11%
SEP-2020	13 87%	1336 28%	2 13%	2440 51%	0 0%	498 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1444 30%	5 29%	2424 50%	0 0%	493 10%	0 0%	30 1%	2 12%	493 10%
NOV-2020	8 36%	1540 31%	9 41%	2475 50%	2 9%	480 10%	0 0%	27 1%	3 14%	489 10%
DEC-2020	10 53%	1624 33%	7 37%	2465 49%	2 11%	458 9%	0 0%	27 1%	0 0%	477 10%
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1979 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2056 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 81%	2112 39%	3 19%	2498 46%	0 0%	382 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2154 40%	5 24%	2488 46%	1 5%	375 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 72%	2198 40%	5 20%	2474 46%	2 8%	366 7%	0 0%	23 0%	0 0%	411 8%
OCT-2021	11 73%	2239 41%	3 20%	2475 45%	1 7%	362 7%	0 0%	24 0%	0 0%	398 7%
NOV-2021	17 77%	2314 42%	4 18%	2464 45%	1 5%	347 6%	0 0%	24 0%	0 0%	392 7%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	55	0.75	761	10.34	153	2.08
FEB-2020	1573	21.46	1154	15.75	3643	49.71	55	0.75	757	10.33	147	2.01
MAR-2020	1540	20.85	1134	15.35	3755	50.83	57	0.77	759	10.27	142	1.92
APR-2020	1522	20.55	1129	15.24	3807	51.39	57	0.77	750	10.12	143	1.93
MAY-2020	1512	20.44	1111	15.02	3830	51.78	56	0.76	748	10.11	140	1.89
JUN-2020	1458	19.79	1084	14.71	3881	52.67	55	0.75	752	10.21	138	1.87
JUL-2020	1420	19.36	1058	14.43	3935	53.66	57	0.78	729	9.94	134	1.83
AUG-2020	1375	18.95	1026	14.14	3944	54.36	66	0.91	714	9.84	130	1.79
SEP-2020	1336	18.47	980	13.55	3999	55.28	79	1.09	710	9.81	130	1.80
OCT-2020	1308	18.00	964	13.27	4058	55.86	101	1.39	701	9.65	133	1.83
NOV-2020	1287	17.53	946	12.89	4128	56.24	159	2.17	697	9.50	123	1.68
DEC-2020	1272	17.32	924	12.58	4152	56.52	177	2.41	703	9.57	118	1.61
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1232	16.70	894	12.12	4226	57.29	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4384	58.76	352	4.72	702	9.41	99	1.33
AUG-2021	1091	14.60	817	10.94	4388	58.73	377	5.05	701	9.38	97	1.30
SEP-2021	1073	14.41	812	10.91	4379	58.82	394	5.29	695	9.34	92	1.24
OCT-2021	1057	14.20	809	10.86	4395	59.02	406	5.45	687	9.23	92	1.24
NOV-2021	1040	13.93	804	10.77	4410	59.08	435	5.83	684	9.16	91	1.22

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	8	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	11	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	2	2	2	3	260

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12525	4021
FEB-2020	12557	4039
MAR-2020	12558	4030
APR-2020	12536	4006
MAY-2020	12526	3994
JUN-2020	12503	3972
JUL-2020	12480	3939
AUG-2020	12448	3915
SEP-2020	12411	3887
OCT-2020	12389	3875
NOV-2020	12403	3876
DEC-2020	12380	3837
JAN-2021	12389	3839
FEB-2021	12381	3833
MAR-2021	12379	3822
APR-2021	12368	3809
MAY-2021	12363	3797
JUN-2021	12364	3791
JUL-2021	12386	3811
AUG-2021	12380	3817
SEP-2021	12349	3785
OCT-2021	12337	3777
NOV-2021	12340	3768

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7464
Nov-2021

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Nov-2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Nov-2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Nov-2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Nov-2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Nov-2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	8	8	6
	35-49	10	11	6
	50+	29	41	20
	Total HSDA:	47	60	32
KOOTENAY BOUNDARY	0-19	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	74	101	58
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	407	549	312
THOMPSON/CARIBOO/ SHUSWAP	20-34	21	21	14
	35-49	69	75	47
	50+	116	188	91
	Total HSDA:	206	284	152
Total HA:		734	994	554

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		734	994	554

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	141	195	102
Male	593	799	452

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	554	56	610	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)



4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	23	13
	5 years or more	13	10
	<5 years	11	9
	Total HSDA:	47	32
KOOTENAY BOUNDARY	10 years or more	47	35
	5 years or more	15	11
	<5 years	12	12
	Total HSDA:	74	58
OKANAGAN	10 years or more	262	192
	5 years or more	89	75
	<5 years	56	45
	Total HSDA:	407	312
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	131	100
	5 years or more	43	32
	<5 years	32	20
	Total HSDA:	206	152
Total HA:		734	554

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	463	340
5 years or more	160	128
<5 years	111	86
Total HA:	734	554

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	14	29
KOOTENAY BOUNDARY	77	130	26	52
OKANAGAN	232	978	53	297
THOMPSON/CARIBOO/SHUSWAP	143	537	36	133
Total:	503	1715	129	511

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	111

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	27
	35-49	95	101	59
	50+	244	336	183
	Total HSDA:	378	478	275
FRASER NORTH	20-34	119	119	82
	35-49	355	379	265
	50+	625	986	482
	Total HSDA:	1099	1484	829
FRASER SOUTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1018	1348	815
Total HA:		2495	3310	1919

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	10
	20-34	266	270	193
	35-49	755	819	563
	50+	1464	2211	1153
Total HA:		2495	3310	1919

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	607	773	440
Male	1888	2537	1479

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1919	53	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	231	171
	5 years or more	84	57
	<5 years	63	47
	Total HSDA:	378	275
FRASER NORTH	10 years or more	674	483
	5 years or more	241	192
	<5 years	184	154
	Total HSDA:	1099	829
FRASER SOUTH	10 years or more	615	480
	5 years or more	228	185
	<5 years	175	150
	Total HSDA:	1018	815
Total HA:		2495	1919

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1520	1134
	5 years or more	553	434
	<5 years	422	351
Total HA:		2495	1919

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribers in BC-CfE Registries
FRASER Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	142	513	30	58
FRASER NORTH	256	1618	47	223
FRASER SOUTH	225	1665	54	489
Total:	623	3796	131	770

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	186
FRASER NORTH	682
FRASER SOUTH	451
Total:	1319

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		353	512
RICHMOND	20-34	34	35	18
	35-49	44	46	36
	50+	111	161	92
	Total HSDA:	189	242	146
VANCOUVER	0-19	11	11	10
	20-34	436	454	283
	35-49	1285	1430	920
	50+	2920	5123	2108
	Total HSDA:	4652	7018	3321
Total HA:		5194	7772	3757

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	11
	20-34	500	519	323
	35-49	1414	1569	1020
	50+	3268	5672	2403
Total HA:		5194	7772	3757

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	609	954	449
Male	4583	6816	3308
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3757	55	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	213	174
	5 years or more	77	66
	<5 years	63	50
	Total HSDA:	353	290
RICHMOND	10 years or more	113	87
	5 years or more	32	23
	<5 years	44	36
	Total HSDA:	189	146
VANCOUVER	10 years or more	3093	2133
	5 years or more	929	691
	<5 years	630	497
	Total HSDA:	4652	3321
Total HA:		5194	3757

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3419	2394
5 years or more	1038	780
<5 years	737	583
Total HA:	5194	3757

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	182	409	55	81
RICHMOND	43	297	8	92
VANCOUVER	653	11220	211	5322
Total:	878	11926	274	5495

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	78

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		338	493
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		122	169
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		781	1110
Total HA:		1241	1772	961

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	117	127	80
	35-49	286	332	226
	50+	832	1307	650
Total HA:		1241	1772	961

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	219	313	171
Male	1022	1459	790

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	961	55	590	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	202	161
	5 years or more	78	62
	<5 years	58	46
	Total HSDA:	338	269
NORTH VANCOUVER ISLAND	10 years or more	81	68
	5 years or more	29	20
	<5 years	12	11
	Total HSDA:	122	99
SOUTH VANCOUVER ISLAND	10 years or more	469	334
	5 years or more	155	126
	<5 years	157	133
	Total HSDA:	781	593
Total HA:		1241	961

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	752	563
	5 years or more	262	208
	<5 years	227	190
Total HA:		1241	961

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	903	73	197
NORTH VANCOUVER ISLAND	152	273	44	72
SOUTH VANCOUVER ISLAND	220	1877	42	570
Total:	575	3053	159	839

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	57
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	125
Total:	223

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	46	57	25
NORTH WEST	20-34	*	6	0
	35-49	*	38	18
	50+	*	72	37
	Total HSDA:	70	116	55
NORTHERN INTERIOR	0-19	6	6	*
	20-34	22	24	*
	35-49	55	70	*
	50+	110	184	*
	Total HSDA:	193	284	147
Total HA:		309	457	227

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	30	34	*
	35-49	98	130	*
	50+	175	287	*
Total HA:		309	457	227

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	171	78
Male	194	286	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	227	52	565	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	28	*
	5 years or more	7	*
	<5 years	11	*
	Total HSDA:	46	25
NORTH WEST	10 years or more	45	34
	5 years or more	16	14
	<5 years	9	7
	Total HSDA:	70	55
NORTHERN INTERIOR	10 years or more	94	75
	5 years or more	64	46
	<5 years	35	26
	Total HSDA:	193	147
Total HA:		309	227

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	167	124
5 years or more	87	62
<5 years	55	41
Total HA:	309	227

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	61	4	*
NORTH WEST	82	167	17	*
NORTHERN INTERIOR	118	482	21	*
Total:	239	710	42	229

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	13
Total:	39

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	11	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	27	44	15
	THOMPSON/CARIBOO/SHUSWAP	25	49	16
	Total HA:	65	113	42
FRASER	FRASER EAST	34	46	22
	FRASER NORTH	54	91	42
	FRASER SOUTH	85	119	61
	Total HA:	173	256	125
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	29	52	26
	RICHMOND	8	13	6
	VANCOUVER	469	891	366
	Total HA:	506	956	398
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	81	39
	NORTH VANCOUVER ISLAND	14	25	12
	SOUTH VANCOUVER ISLAND	45	89	35
	Total HA:	106	195	86
NORTHERN	NORTH EAST	11	15	8
	NORTH WEST	31	65	26
	NORTHERN INTERIOR	69	112	59
	Total HA:	111	192	93
Total:		961	1712	744

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	354	613	269
Male	607	1099	475

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	744	53	530	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

